Methods for treating cancer and non-neoplastic conditions

Abstract

Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

1 - 8 . (canceled) 
     
     
         9 . A compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, racemate or stereoisomer thereof, for use in treating cancer in a human, wherein the cancer is acute leukemia; acute lymphocytic leukemia; acute myelocytic leukemia; chronic leukemia; polycythemia vera; lymphoma; or multiple myeloma. 
       
     
     
         10 . The use of  claim 9 , wherein the acute myelocytic leukemia is selected from myeloblastic, promyelocytic, myelomonocytic, monocytic or erythroleukemia leukemia or myelodysplastic syndrome. 
     
     
         11 . The use of  claim 9 , wherein the chronic leukemia is selected from chronic myelocytic leukemia, chronic lymphocytic leukemia or hairy cell leukemia. 
     
     
         12 . The use of  claim 9 , wherein the lymphoma is selected from Hodgkin's disease or non-Hodgkin's disease. 
     
     
         13 . The use of  claim 9 , wherein the multiple myeloma is selected from smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma or plasma cell leukemia. 
     
     
         14 . A compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, racemate or stereoisomer thereof, for use in treating cancer in a human wherein the cancer is acute leukemia; acute lymphocytic leukemia; acute myelocytic leukemia; chronic leukemia; polycythemia vera; lymphoma; or multiple myeloma. 
       
     
     
         15 . The use of  claim 14 , wherein the acute myelocytic leukemia is selected from myeloblastic, promyelocytic, myelomonocytic, monocytic or erythroleukemia leukemia or myelodysplastic syndrome. 
     
     
         16 . The use of  claim 14 , wherein the chronic leukemia is selected from chronic myelocytic leukemia, chronic lymphocytic leukemia or hairy cell leukemia. 
     
     
         17 . The use of  claim 14 , wherein the lymphoma is selected from Hodgkin's disease or non-Hodgkin's disease. 
     
     
         18 . The use of  claim 14 , wherein the multiple myeloma is selected from smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma or plasma cell leukemia.